Galecto Inc
$ 22.14
14.48%
03 Dec - close price
- Market Cap 35,258,400 USD
- Current Price $ 22.14
- High / Low $ 22.19 / 17.75
- Stock P/E N/A
- Book Value 5.02
- EPS -12.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -1.10 %
- 52 Week High 33.60
- 52 Week Low 2.01
About
Galecto, Inc. is a clinical-stage biotechnology company based in Copenhagen, Denmark, specializing in the development of innovative therapies aimed at addressing unmet medical needs in fibrosis, cancer, and inflammation. Utilizing its proprietary galectin technology platform, Galecto targets fundamental biological pathways to create potential treatments that could significantly improve patient outcomes. The company boasts a robust pipeline of drug candidates, underscoring its commitment to advancing healthcare through scientific excellence. As a player in the dynamic biopharmaceutical sector, Galecto presents a compelling investment opportunity for those focused on transformative therapeutic solutions.
Analyst Target Price
$32.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-11 | 2025-04-28 | 2025-03-19 | 2024-11-01 | 2024-08-05 | 2024-04-29 | 2024-03-08 | 2023-11-06 | 2023-07-31 | 2023-04-28 | 2023-03-09 |
| Reported EPS | -2.3609 | -2.6 | -1.916 | -5 | -3.39 | -0.16 | -0.2 | -0.24 | -0.3 | -0.41 | -0.51 | -0.55 |
| Estimated EPS | None | 0 | None | -2.82 | -3.7 | -0.31 | -0.41 | -0.31 | -0.47 | -0.59 | -0.62 | -0.57 |
| Surprise | 0 | -2.6 | 0 | -2.18 | 0.31 | 0.15 | 0.21 | 0.07 | 0.17 | 0.18 | 0.11 | 0.02 |
| Surprise Percentage | None% | None% | None% | -77.305% | 8.3784% | 48.3871% | 51.2195% | 22.5806% | 36.1702% | 30.5085% | 17.7419% | 3.5088% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GLTO
2025-11-19 10:37:00
Galecto, Inc. has announced its Q3 earnings, revealing a strategic pivot towards developing oncology and severe liver disease product candidates, GB3226 and GB1211. The company reported a net loss of $3.1 million for the quarter and $9.1 million for the nine months ending September 30, 2025, with cash and cash equivalents significantly reduced. Despite financial challenges and the need for additional funding, Galecto plans to submit an investigational new drug application for GB3226 to the FDA, focusing on securing capital for its R&D efforts.
2025-11-10 07:00:00
Galecto (NASDAQ:GLTO) has completed its acquisition of Damora Therapeutics and secured $284.9 million through a Series C private placement. This financing is expected to fund operations into 2029, supporting the advancement of Damora’s anti-mutCALR portfolio, including the lead asset DMR-001, which targets Myeloproliferative Neoplasms. Key milestones include an IND submission for DMR-001 in mid-2026 and Phase 1 proof-of-concept data anticipated in 2027.
2025-11-06 21:43:00
Galecto, Inc. reported its Q3 2025 financial and operational results, highlighting constructive feedback from the FDA on its pre-IND submission for GB3226, a dual inhibitor for acute myeloid leukemia. The company plans to submit an IND in early 2026 and initiate a Phase 1 trial, supported by preclinical data. Financially, Galecto had $7.6 million in cash as of September 30, 2025, and reported a net loss of $3.1 million for the quarter, indicating a need for additional capital for future operations.
2025-10-16 19:28:24
This article highlights five stocks—POET Technologies, Oracle, Nuburu, Galecto, and TMC The Metals Company—that were on investors' radars due to significant price movements and company-specific news. POET Technologies surged after a major private placement, Nuburu rose following a strategic acquisition, and Galecto experienced a speculative rally. Oracle saw a decline due to financial challenges related to Nvidia chips, while TMC The Metals Company benefited from renewed interest in the metals sector.
2025-10-11 07:21:00
Galecto Inc. (NASDAQ:GLTO) stock surged 360% following its acquisition of Damora Therapeutics, a privately held biotechnology firm specializing in treatments for Myeloproliferative Neoplasms (MPNs). This acquisition allows Galecto to advance a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, including a potentially best-in-class monoclonal antibody, DMR-001. Galecto also secured approximately $284.9 million in private placement, extending its financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 by 2027.
2025-10-07 21:35:00
This article highlights five trending stocks, POET Technologies, Oracle, Nuburu, Galecto, and TMC The Metals Company, that garnered significant investor attention on a day when major U.S. indices closed lower. Key movements included POET's climb due to a private placement, Oracle's dip following Nvidia chip rental issues, Nuburu's surge after a strategic acquisition, Galecto's dramatic rally despite no news, and TMC's rise fueled by investments in the metals sector.
